Prostate cancer (PCa) remains a leading cause of cancer-related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance. Through integrative bioinformatics analysis of GEO datasets, we found SLC3A1 significantly upregulated in Enza-resistant PCa models. WGCNA and single-cell RNA sequencing confirmed its association with adverse prognosis and activation of key survival pathways. Functional experiments demonstrated that SLC3A1 knockdown reduced AKT phosphorylation, and inhibited colony formation in LNCaP cells. Conversely, SLC3A1 overexpression activated PI3K-AKT signaling, suppressed ferroptosis and conferred Enza resistance in vitro and in vivo. These results reveal SLC3A1 is a promising therapeutic target for advanced prostate cancer.
Keywords: GEO, SLC3A1, WGCNA, enzalutamide, prostate cancer
Journal of biochemical and molecular toxicology
Journal Article
English
42606826
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.